H. Aytan Et Al. , "Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.," The Australian & New Zealand journal of obstetrics & gynaecology , vol.47, pp.321-5, 2007
Aytan, H. Et Al. 2007. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.. The Australian & New Zealand journal of obstetrics & gynaecology , vol.47 , 321-5.
Aytan, H., Caliskan, A. C., Demirturk, F., Aytan, P., & Koseoglu, D., (2007). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.. The Australian & New Zealand journal of obstetrics & gynaecology , vol.47, 321-5.
Aytan, H Et Al. "Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.," The Australian & New Zealand journal of obstetrics & gynaecology , vol.47, 321-5, 2007
Aytan, H Et Al. "Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.." The Australian & New Zealand journal of obstetrics & gynaecology , vol.47, pp.321-5, 2007
Aytan, H. Et Al. (2007) . "Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.." The Australian & New Zealand journal of obstetrics & gynaecology , vol.47, pp.321-5.
@article{article, author={H Aytan Et Al. }, title={Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.}, journal={The Australian & New Zealand journal of obstetrics & gynaecology}, year=2007, pages={321-5} }